Histafen 50mg 2p x 20 tablets — Made in Latvia — Free Delivery

Pharmacological properties

Pharmacodynamics. Sequifenadine is a blocker of H1-receptors, as well as a moderate blocker of 5-HT1-serotonin receptors, thus reducing the severity of the action of allergy mediators, histamine and serotonin. a feature of the preparation is that it has an antihistaminic effect not only due to blockade of h1-receptors, but also by reducing the concentration of histamine in tissues by accelerating its metabolism by the enzyme diamine oxidase, which breaks down endogenous histamine. sekhifenadine prevents or reduces the severity of the spasmodic effect of histamine and serotonin on the smooth muscles of the bronchi, intestines, blood vessels, reduces capillary permeability, has a pronounced antipruritic effect. sekhifenadine affects the immunological reactivity of the body, reducing the number of antibody-forming and rosette-forming cells in the spleen, bone marrow, lymph nodes, and also reduces the increased concentration of immunoglobulins of classes a and g.

The preparation poorly penetrates the BBB, which explains the absence of a pronounced inhibitory effect on the central nervous system, however, in some cases, with individual hypersensitivity to the preparation, a slight sedative effect may be noted. Sekhifenadine does not affect the biochemical parameters of blood and urine (including the concentration of glucose and cholesterol in the blood), blood pressure, ECG parameters, does not increase the latent period of the conditioned reflex and does not affect EEG parameters.

Pharmacokinetics. The preparation  is rapidly absorbed in the gastrointestinal tract. Cmax in blood plasma is reached after 1-2 hours. It is metabolized in the liver, forming a pharmacologically inactive metabolite. After a single dose of 50 mg, T½ from blood plasma is 12 hours, and after repeated doses, T½ decreases to 5.8 hours. The use of the preparation does not cause cumulation. More than 20% of the dose is excreted by the kidneys and 50% by the intestines. About 30% of the dose is excreted unchanged, 40-50% - in the form of metabolites.

Indications

Acute and chronic allergic diseases: pollinosis, allergic rhinitis, rhinosinusopathies (atopic and infectious-allergic); allergic reactions associated with the use of medicines, food products, household chemicals; allergic and non-allergic diseases that are accompanied by itching (allergic or atopic dermatitis, skin vasculitis, neurodermatitis, lichen planus); atopic and infectious-allergic dermatitis in children over 12 years of age; prevention of allergic diseases (before the period of seasonal exacerbation) and supportive therapy.

Application

It is taken orally after meals with water.

Adults

Acute and chronic allergic diseases: 50-100 mg 2-3 times a day.

Allergic and non-allergic diseases, accompanied by itching: 50-100 mg 2-3 times a day.

The therapeutic effect usually develops within 3 days from the start of therapy. The duration of the course of treatment is 5-15 days. If necessary, repeat the course of treatment.

Prevention of allergic diseases (until the period of their seasonal exacerbation) and for maintenance therapy: 50 mg 2 times a day. It is recommended to start taking the preparation 2 weeks before the expected allergic reaction. If one or more doses of the preparation are missed, treatment is continued at the previously prescribed doses.

Children over the age of 12

Atopic and infectious-allergic dermatitis: 50 mg 3 times a day. The course of treatment is 7 days.

Contraindications

Hypersensitivity to sechifenadine and other components of the preparation, attacks of BA, pregnancy and lactation, concomitant use of MAO inhibitors.

Side effects

Histafen is generally well tolerated.

Possible side reactions:

• from the digestive tract: dry mouth, soreness in the epigastric region, dyspeptic symptoms (especially after taking the preparation on an empty stomach); in isolated cases - an increase in appetite (especially in the first days of treatment, no discontinuation of the preparation or a significant reduction in its dose is required);
• from the blood system: leukopenia;
• from the nervous system: headache, drowsiness (in most cases, drowsiness decreases or disappears after 2–5 days from the start of treatment), rarely - agitation, insomnia (most often when using the preparation in a high dose);
• others: menstrual irregularities, mild diuretic effect.

Special instructions

Care should be taken when prescribing the preparation to patients with impaired renal function (treatment begins with the appointment in a minimum dose), severe diseases of the cardiovascular system, gastrointestinal tract, liver.

The preparation contains lactose, therefore, patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use the preparation. During the period of treatment, you should refrain from drinking alcohol.

Use during pregnancy and lactation. The safety of using sechifenadine during pregnancy has not been established. Therefore, the preparation is contraindicated in women during this period. During breastfeeding, the use of antihistamines is not recommended due to the possibility of a negative effect on the central nervous system of an infant. If necessary, use of the preparation should stop breastfeeding. There are no clinical data on the use of the preparation in children, therefore, the preparation is not prescribed to patients of this age category.

Children. The preparation is used in children aged 12 years and older with atopic and infectious-allergic dermatitis.

The ability to influence the reaction rate when driving vehicles or other mechanisms. Persons whose work requires the speed of physical and mental reactions (drivers of vehicles, etc.) must first establish (by short-term use) whether the preparation causes a sedative effect in them. In case of sedation, you should refrain from driving.

Interactions

The use of histafen can be combined with the use of topical preparations (ointments, compresses, eye drops, nasal drops). Histafen does not enhance the inhibitory effect of hypnotics and preparations containing alcohol on the central nervous system. the use of the preparation while taking MAO inhibitors is contraindicated.

Overdose

The preparation is low-toxic. symptoms: dryness of the mucous membranes, headache, vomiting, abdominal pain and dyspeptic symptoms. treatment: symptomatic therapy. no specific antidote known.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ° C.